Covered recipient · General Payments record
JEANNE L BEATTIE
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2021
$2,482.78
- Reported across 126 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2021 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $310.70 | 17 |
By paying entity
PY2021 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $72.30 | 3 |
| ABBVIE INC. | $59.16 | 4 |
| LivaNova USA, Inc. | $44.65 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $19.53 | 1 |
| Zogenix Inc. | $18.92 | 1 |
| UCB, Inc. | $17.15 | 1 |
| Lundbeck LLC | $16.56 | 1 |
| Greenwich Biosciences, Inc. | $16.39 | 1 |
| Biohaven Pharmaceuticals, Inc. | $15.92 | 1 |
| Supernus Pharmaceuticals, Inc. | $15.66 | 1 |
| Teva Pharmaceuticals USA, Inc. | $14.46 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2021 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $15.48 | 03/04/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794014891 | CMS |
| AbbVie Inc. | $18.82 | 04/27/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794014895 | CMS |
| AbbVie Inc. | $12.28 | 05/14/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794014899 | CMS |
| AbbVie Inc. | $12.58 | 06/10/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794014903 | CMS |
| Amgen Inc. | $22.26 | 01/27/2021 | Food and Beverage | Undisputed | 01/23/2026 | 825395177 | CMS |
| Amgen Inc. | $29.72 | 05/05/2021 | Food and Beverage | Undisputed | 01/23/2026 | 825395181 | CMS |
| Amgen Inc. | $20.32 | 08/18/2021 | Food and Beverage | Undisputed | 01/23/2026 | 825395185 | CMS |
| Biohaven Pharmaceuticals, Inc. | $15.92 | 08/25/2021 | Food and Beverage | Undisputed | 01/23/2026 | 852421509 | CMS |
| Greenwich Biosciences, Inc. | $16.39 | 04/08/2021 | Food and Beverage | Undisputed | 01/23/2026 | 841843137 | CMS |
| LivaNova USA, Inc. | $32.25 | 06/17/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844254239 | CMS |
| LivaNova USA, Inc. | $12.40 | 07/28/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844254243 | CMS |
| Lundbeck LLC | $16.56 | 02/09/2021 | Food and Beverage | Undisputed | 01/23/2026 | 845897997 | CMS |
| Novartis Pharmaceuticals Corporation | $19.53 | 02/03/2021 | Food and Beverage | Undisputed | 01/23/2026 | 812603927 | CMS |
| Supernus Pharmaceuticals, Inc. | $15.66 | 04/20/2021 | Food and Beverage | Undisputed | 01/23/2026 | 845005007 | CMS |
| Teva Pharmaceuticals USA, Inc. | $14.46 | 06/29/2021 | Food and Beverage | Undisputed | 01/23/2026 | 839711949 | CMS |
| UCB, Inc. | $17.15 | 05/26/2021 | Food and Beverage | Undisputed | 01/23/2026 | 807362403 | CMS |
| Zogenix Inc. | $18.92 | 02/24/2021 | Food and Beverage | Undisputed | 01/23/2026 | 854235365 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021
- Generated from
- OP_DTL_GNRL_PGYR2021_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.